SELLAS Life Sciences Group, Inc. (SLS)
Current
- (-)
After Hours
Rating Performance
Rating Return
-28.44% vs
Rating Accuracy
0% (0 of 1*)
Rating Return
-57.07% vs
Rating Accuracy
0% (0 of 2*)
Rating Return
-57.07% vs
Rating Accuracy
0% (0 of 2*)
Rating Return
+96.24% vs
Rating Accuracy
66.67% (2 of 3*)
FV Performance
FV Accuracy
5 Hits (71.43% Hit Rate)
FV Avg. Distance
+139.16%
FV Accuracy
6 Hits (66.67% Hit Rate)
FV Avg. Distance
+122.5%
FV Accuracy
6 Hits (31.58% Hit Rate)
FV Avg. Distance
+122.5%
FV Accuracy
19 Hits (44.19% Hit Rate)
FV Avg. Distance
+40.79%
*There is a current rating on the stock that is included in these numbers based on its performance so far
About
CEO
Angelos M. Stergiou
Employees
5
Industry
Oncology Biopharmaceuticals
Sector
Healthcare
Headquarters
New York
Exchange
NASDAQ
Summary Stats
Market Cap
68.6M
Revenue
1M
Net Income
-38.8M
EPS
-$2.29
Price-to-Earnings
-1.46
Price-to-Book
3.6
Debt-to-Equity
0.69
News
Analyst Ratings
Price targets projected by 1 analyst
High
$8.00
Average
$8.00
Low
$8.00
Ratings calculated by 0 analysts
Buy
0
Hold
0
Sell
0
Last Dividend
Amount
-
Dividend Date
-
Frequency
-
Dividend Yield
Earnings
Most Recent Earnings
Last Earnings for Q3 2022
Above by $0.05
-$0.34 +12.8%
-0.39
-0.45
Up 24%
Actual vs Estimates
XX
xxx
Upcoming Estimates Unavailable
-
-
-
--